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A bs tr ac t
Background
Undescended testis, which is a risk factor for testicular cancer, is usually treated sur-
gically, but whether the age at treatment has any effect on the risk is unclear. We stud-
ied the relation between the age at treatment for undescended testis and the risk of 
testicular cancer.
Methods
We identified men who underwent orchiopexy for undescended testis in Sweden be-
tween 1964 and 1999. Cohort subjects were identified in the Swedish Hospital Dis-
charge Register and followed for the occurrence of testicular cancer through the Swed-
ish Cancer Registry. Vital statistics and data on migration status were taken from the 
Register of Population and Population Changes for the years 1965 through 2000. We 
estimated the relative risk of testicular cancer using Poisson regression of standard-
ized incidence ratios, comparing the risk in the cohort with that in the general popu-
lation. We also analyzed the data by means of Cox regression, using internal compari-
son groups.
Results
The cohort consisted of 16,983 men who were surgically treated for undescended testis 
and followed for a total of 209,984 person-years. We identified 56 cases of testicular 
cancer during follow-up. The relative risk of testicular cancer among those who un-
derwent orchiopexy before reaching 13 years of age was 2.23 (95% confidence inter-
val [CI], 1.58 to 3.06), as compared with the Swedish general population; for those 
treated at 13 years of age or older, the relative risk was 5.40 (95% CI, 3.20 to 8.53). The 
effect of age at orchiopexy on the risk of testicular cancer was similar in comparisons 
within the cohort.
Conclusions
Treatment for undescended testis before puberty decreases the risk of testicular 
cancer.
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Undescended testis, or cryptorchi-dism, which occurs in 2 to 5% of boys born at term, is one of the most common con-
genital abnormalities.1 Cryptorchidism is associ-
ated with impaired fertility and is a risk factor for 
testicular cancer. Among men who have had un-
descended testis, the risk of cancer is increased two 
to eight times, and 5 to 10% of all men with tes-
ticular cancer have a history of cryptorchidism.1,2 
However, it is unknown whether cryptorchidism 
and testicular cancer have a common cause, or 
whether cryptorchidism is in itself a cause of tes-
ticular cancer.
Testes that are undescended at birth may de-
scend spontaneously during early life, but seldom 
thereafter. By 12 months of age, about 1% of all 
boys have cryptorchidism.1,3 Treatment for persis-
tent cryptorchidism is generally orchiopexy, a sur-
gical correction in which the testicle is placed and 
fixed in the scrotum. There is evidence that post-
natal germ-cell development deteriorates in the 
undescended testis after the first year, and perhaps 
for this reason, the risk of infertility increases 
with age.1,4,5 The recommended age for orchio-
pexy has therefore been successively lowered, and 
the procedure is now recommended for patients 
younger than 2 years old and even as young as 
6 months old.4,6
The question of whether the age at treatment 
has any effect on the risk of testicular cancer is 
controversial. According to the predominant view, 
the mechanism leading to testicular cancer is pres-
ent before birth and the risk of cancer is largely 
determined in utero or early in life.7,8 If this view 
is correct, then the age at surgical correction 
should not be related to the rate of testicular can-
cer. Some studies suggest, however, that orchio-
pexy at an early age decreases the risk of testicu-
lar cancer. Even so, most of these studies used 
retrospectively collected data, and all of them were 
too small to produce conclusive results.9-13 We in-
vestigated the risk of testicular cancer according 
to the age at orchiopexy in a cohort of almost 
17,000 Swedish men who were surgically treated 
for cryptorchidism between 1964 and 1999.
Me thods
The Registries
We used data from the Swedish Hospital Discharge 
Register to assemble the study cohort, which was 
followed from 1965 to 2000 through linkage to 
the Swedish Cancer Registry and the Register of 
Population and Population Changes. Linkage was 
performed on the basis of the national registration 
number, a unique personal identifier referred to 
in all hospital records and official registries in 
Sweden.
In 1964, the Swedish National Board of Health 
and Welfare initiated the Hospital Discharge Reg-
ister, which compiles data on individual discharges 
from Swedish public hospitals. Virtually all pa-
tients in Sweden are treated at public hospitals, 
making the Discharge Register representative of 
hospitalizations in the Swedish population. Each 
record contains medical and administrative data, 
including the dates of admission and discharge, 
surgical procedures performed, the main diagno-
sis at discharge, and up to five contributory diag-
noses. The surgical procedures were coded from 
1964 to 1996 according to the Swedish Classification 
of Operations and Major Procedures, first through sixth 
editions, and from 1997 onward according to the 
Classification of Surgical Procedures, 1997 edition. The 
diagnoses at discharge were coded according to 
the Swedish version of the International Classification 
of Diseases, with the 7th revision (ICD-7) used for 
the years 1964 through 1968, the 8th revision 
(ICD-8) for 1969 through 1986, the 9th revision 
(ICD-9) for 1987 through 1996, and the 10th revi-
sion (ICD-10) thereafter.
In 1964, the Discharge Register covered 6 of the 
26 health care regions in Sweden. Gradually, more 
hospitals were included, and by 1975, 16 health 
care regions were fully covered14 (including the 
three largest cities in Sweden: Stockholm, Gothen-
burg, and Malmö). Since 1987, the registry has 
covered all hospitals in Sweden.
The Swedish Cancer Registry was established 
in 1958 and obtains mandatory reported data from 
both clinicians and pathologists on all newly di-
agnosed malignant neoplasms. Information on 
the site and histopathological features of the tu-
mors is recorded. The registry is estimated to be 
more than 95% complete.15 The Register of Popu-
lation and Population Changes contains the offi-
cial Swedish population data, including dates of 
death and migration; the data have been available 
since 1960.
The Cohort
We confined our study cohort to all subjects in 
the Discharge Register who had received a diag-
nosis of cryptorchidism (main or contributory dis-
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charge diagnosis ICD-7 code 757.00, ICD-8 code 
752.10, ICD-9 code 752F, or ICD-10 code Q53.0, 
Q53.1, Q53.2, or Q53.9) between January 1964 and 
December 1999 and who had been treated with 
orchiopexy (surgical procedure code 6790, KFH00, 
or KFH10) before 20 years of age. The restriction 
to those who underwent surgery before 20 years 
of age minimized the influence of selection bias 
due to, for instance, referral of men seeking treat-
ment for infertility to the urology department.
One subject in whom testicular cancer had al-
ready been diagnosed, 205 subjects who emigrated 
from Sweden after orchiopexy and did not immi-
grate back to Sweden before the beginning of their 
follow-up, and 12 subjects with conflicting infor-
mation on sex or date of orchiopexy were excluded 
from the study cohort, leaving 16,983 subjects for 
the analysis. Among 2667 (15.7%) subjects who 
were surgically treated for cryptorchidism more 
than once, we used the date of the last admission 
as the index date of orchiopexy.
The study was approved by the ethics commit-
tee of the Karolinska Institute. Informed consent 
was not required.
Statistical Analysis
The members of the cohort were followed from 
15 years of age or the age at orchiopexy plus 1 year, 
whichever occurred later, to the date of diagnosis 
of germ-cell testicular cancer (ICD-7 code 178), the 
age of 55, emigration, death, or December 31, 2000, 
whichever occurred first. The first year after or-
chiopexy was excluded to reduce the risk of selec-
tion bias. The germ-cell testicular cancers we in-
cluded were seminomas and nonseminomas, the 
latter encompassing teratomas, choriocarcinomas, 
yolk-sac tumors, embryonal carcinomas, and mixed 
germ-cell tumors.
We estimated the relative risk of testicular can-
cer by calculating the standardized incidence ratio 
(the observed number of cases of testicular cancer 
divided by the expected number). Expected num-
bers of testicular cancer were based on the 5-year 
age- and period-specific rates in the Swedish gen-
eral population. We estimated 95% confidence 
intervals (CIs) assuming a Poisson distribution. 
Analyses were also stratified according to age at 
orchiopexy and calendar period of orchiopexy. In 
categorizing age at orchiopexy, we focused on the 
ages around puberty. Categories are therefore 
smaller for the group between 10 and 15 years of 
age and larger for ages before and after. Thirteen 
years of age was set a priori as the cutoff for 
analyses of surgery before and after puberty.
We used Cox regression analysis, with age as 
the temporal axis, to estimate the hazard ratio for 
testicular cancer associated with age at orchiopexy 
in comparisons within the cohort. Covariates in-
cluded in the model were the calendar period of 
follow-up (1965 to 1990, 1991 to 1995, and 1996 
to 2000), calendar period of orchiopexy, and region 
where the orchiopexy was performed (two cate-
gories: the three largest cities in Sweden and the 
rest of Sweden). There is colinearity among birth 
cohort, age at orchiopexy, and calendar period of 
orchiopexy (e.g., a child operated on at 5 years of 
age in 1970 must have been born in 1964 or 1965). 
To analyze the effect of age at orchiopexy adjusted 
by calendar period of orchiopexy, we therefore 
used only three categories for the latter variable 
(1964 to 1969, 1970 to 1974, and 1975 to 1999), 
assuming no period effect after 1974. Both visual 
inspection of a graph (with the log of the cumu-
lative hazard on the y axis and the log of the sur-
vival time on the x axis) and a formal test based on 
Schoenfeld residuals (P = 0.68) indicated that the 
proportional-hazard assumption was met. There 
was no evidence of interaction between the calen-
dar period of follow-up and the effect of age at 
orchiopexy.
We also conducted a sensitivity analysis, re-
stricting the cohort to men born between 1964 
and 1980, among whom the estimate of the effect 
of age at orchiopexy could not be biased by the 
lack of information about orchiopexy before 1964 
(when the Discharge Register was established) or 
by the termination of the follow-up at 2000.
R esult s
The cohort consisted of 16,983 men who were sur-
gically treated for cryptorchidism and followed 
for a mean (±SD) period of 12.4±7.4 years, with a 
total of 209,984 person-years at risk. For 679 of the 
subjects, follow-up ended before December 31, 
2000, because of a diagnosis of testicular cancer 
(56), emigration (436), reaching the age of 55 years 
(5), or death (182). The overall mean age at orchio-
pexy was 8.6±3.5 years, and the median age was 
8.5 years. Table 1 lists the main characteristics of 
the cohort.
We identified 56 cases of testicular cancer dur-
ing the follow-up period, as compared with 20 
expected cases, resulting in a standardized inci-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on April 3, 2012. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 356;18 www.nejm.org may 3, 20071838
dence ratio of 2.75 (95% CI, 2.08 to 3.57). The 
standardized incidence ratio for testicular cancer 
among those operated on before the age of 13 
years was 2.23 (95% CI, 1.58 to 3.06), whereas it 
was 5.40 (95% CI, 3.20 to 8.53) for those treated 
at age 13 or later (Table 2). There were no signifi-
cant differences in risk between groups below (P = 
0.81) or above (P = 0.68) the age of 13 years. The 
proportion of men who were 13 years of age or 
older at orchiopexy declined from 27.3% in the 
beginning of the study period to 5.4% during the 
late 1980s (Table 3).
Figure 1 shows the standardized incidence ra-
tios for testicular cancer according to the calendar 
period of orchiopexy among men who underwent 
the surgery before the age of 13 years and among 
those who were surgically treated when they were 
13 years or older. The standardized incidence ra-
tio for all men in the cohort decreased from 8.64 
(95% CI, 4.47 to 15.10) among those operated on 
between 1964 and 1969 to 3.29 (95% CI, 1.95 to 
5.21) for those operated on between 1970 and 
1974, and it did not vary much after that. The rela-
tive difference between the standardized incidence 
Table 1. Characteristics of the Cohort of Men Who Underwent Surgery for Cryptorchidism.
Variable
Men Who 
Underwent Surgery
Person-Years  
of Follow-Up 
Men with  
Testicular Cancer 
number (percent)
Total 16,983 (100) 209,984 (100) 56 (100)
Age at orchiopexy 
0–2 yr 718 (4.2) 4,395 (2.1) 1 (1.8)
3–6 yr 5,139 (30.3) 47,303 (22.5) 8 (14.3)
7–9 yr 5,047 (29.7) 61,172 (29.1) 14 (25.0)
10–12 yr 4,417 (26.0) 65,339 (31.1) 15 (26.8)
13–15 yr 1,217 (7.2) 22,884 (10.9) 12 (21.4)
16–19 yr 445 (2.6) 8,891 (4.2) 6 (10.7)
Calendar year of orchiopexy
1964–1969 542 (3.2) 14,575 (6.9) 12 (21.4)
1970–1974 2,326 (13.7) 50,185 (23.9) 18 (32.1)
1975–1979 3,780 (22.3) 63,030 (30.0) 11 (19.6)
1980–1984 4,714 (27.8) 53,281 (25.4) 10 (17.9)
1985–1989 3,522 (20.7) 22,464 (10.7) 5 (8.9)
1990–1994 1,823 (10.7) 6,002 (2.9) 0
1995–1999 276 (1.6) 447 (0.2) 0
Year of birth
1963 or earlier 2,129 (12.5) 52,038 (24.8) 27 (48.2)
1964–1969 3,524 (20.8) 64,394 (30.7) 14 (25.0)
1970–1974 3,855 (22.7) 50,866 (24.2) 10 (17.9)
1975–1979 3,687 (21.7) 31,293 (14.9) 4 (7.1)
1980–1985 3,788 (22.3) 11,393 (5.4) 1 (1.8)
Type of cancer
Seminoma 23 (41.1)
Nonseminoma 33 (58.9)
Region*
Urban 5,468 (32.2) 71,458 (34.0) 17 (30.4)
Nonurban 11,515 (67.8) 138,526 (66.0) 39 (69.6)
* The urban category includes Sweden’s three largest cities: Stockholm, Gothenburg, and Malmö. Percentages may not 
total 100 because of rounding.
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ratios for those who underwent surgery before the 
age of 13 years and those in whom surgery was 
performed at or after the age of 13 years was close 
to 2 in most of the calendar periods (Fig. 1).
The within-cohort analysis of the effects of age 
at orchiopexy on the risk of testicular cancer were 
consistent with the findings obtained when the 
rates of testicular cancer in the study cohort were 
compared with Swedish national rates (Fig. 2). 
The adjusted hazard ratio for testicular cancer 
among men who were 13 years of age or older 
when surgery was performed, as compared with 
those who were younger at the time of treatment 
was 1.99 (95% CI, 1.00 to 3.95). Analyses restricted 
to men born between 1964 and 1980 revealed a 
hazard ratio of 3.56 (95% CI, 1.34 to 9.47), based 
on 6 cases in which surgery was performed at 13 
years of age or later and 23 cases in which surgery 
was performed at an earlier age.
Discussion
In this cohort study of 16,983 men who were sur-
gically treated for cryptorchidism, we found that 
the risk of testicular cancer among men who were 
treated at 13 years of age or older was approximate-
ly twice that among men who underwent orchio-
pexy before the age of 13. The results indicate that 
early, rather than late, surgical treatment can best 
prevent testicular cancer in boys with cryptorchi-
dism. The results also suggest that the ectopic po-
sition of the testis is a factor in the development 
of testicular cancer.
In our large cohort study, the use of strict 
criteria for identification of cohort members — 
registration with both diagnosis and surgical pro-
cedure — reduced the likelihood of misclassifica-
tion of cryptorchidisism. By starting follow-up 
1 year after the date of surgery and by restricting 
the cohort to men who had been treated before 
reaching 20 years of age, the risk of including co-
hort members who already had testicular cancer 
should have been minimized. Moreover, use of the 
nationwide cancer registry to ascertain outcome 
virtually ensured complete follow-up.
In principle, the gradual inclusion of health 
care regions in the Discharge Register could have 
biased the results. However, the incidence of tes-
ticular cancer in Sweden is fairly homogeneous,16 
and in analyses with an internal comparison 
group, in which we could adjust for the region, 
estimates of risk were similar to those in the 
analysis in which the general population was used 
as the comparison group. For this reason, it is 
unlikely that such a bias had any major influence 
on the results.
The strong effect of the calendar period of or-
chiopexy on the risk of testicular cancer (Fig. 1) 
suggests that unknown risk factors correlated with 
calendar time affect the risk estimates. The effect 
of age at orchiopexy on the risk of testicular can-
cer was, however, essentially constant over calen-
dar periods. Consequently, it is unlikely that the 
factors underlying the effect of the calendar pe-
riod of orchiopexy can explain the effect of age 
at orchiopexy on the risk of testicular cancer.
Other studies have examined the age at or-
chiopexy in relation to the risk of testicular can-
cer.9-13,17-20 Most of these investigations were case–
control studies with small samples. Several suggest 
that the risk of testicular cancer increases with 
age at treatment, with men treated after the age 
of 10 to 15 years at greatest risk.9-13 In our study, 
Table 3. Proportion of Men in the Cohort Who Were 
Treated at 13 Years of Age or Older.
Year* Men Treated at 13 Years of Age or Older 
%
1964–1969 27.3
1970–1974 14.8
1975–1979 10.8
1980–1984 7.2
1985–1989 5.4
* Data are not shown for later years because day-surgery 
orchiopexies were introduced in Sweden in the early 1990s.
Table 2. Standardized Incidence Ratio for Testicular Cancer According to the 
Age at Orchiopexy among Men 15 to 55 Years of Age between 1965 and 2000.*
Age at Orchiopexy
No. of Men  
with Testicular Cancer
Standardized Incidence 
Ratio (95% CI)
All ages 56 2.75 (2.08–3.57)
0–6 yr 9 2.02 (0.93–3.84)
7–9 yr 14 2.35 (1.28–3.94) 
10–12 yr 15 2.27 (1.27–3.74)
13–15 yr 12 5.06 (2.61–8.84)
16–19 yr 6 6.24 (2.29–13.58)
<13 yr 38 2.23 (1.58–3.06)
≥13 yr 18 5.40 (3.20–8.53)
* The Swedish general population was used as the comparison group.
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we could categorize age at orchiopexy into nar-
rower age groups, and we found a sharp increase 
in risk among men treated when they were 13 to 
15 years of age (or older) as compared with those 
treated at the age of 10 to 12 years (or at younger 
ages). It is unlikely that such a sharp threshold can 
be explained by any known confounding factor.
It could be argued that men treated at 13 years 
of age or older had mainly nondescending crypt-
orchidism, whereas a large proportion of men who 
were treated before the age of 13 had conditions 
that may not be associated with testicular cancer, 
such as spontaneously descending testes or retrac-
tile testis. To observe the risk pattern we found, 
however, 25% of the patients treated before 13 
years of age would have to have had nondescend-
ing cryptorchidism, as compared with 100% of the 
patients treated at 13 years of age or older. It there-
fore seems that the ectopic location of the testis 
at puberty explains the increase in risk at age 13. 
It is also believed that the risk of germ-cell cancer 
of the testis is largely determined in utero. The 
results of our study are partly consistent with this 
hypothesis, since the risk was increased in the 
entire cohort, regardless of the age at surgical 
treatment. Our results, however, suggest that pu-
berty, here defined arbitrarily as beginning at the 
age of 13 years, is another crucial event in testicu-
lar carcinogenesis.
Some studies have indicated that the risk of 
testicular cancer in the contralateral testis is in-
creased in men with unilateral cryptorchidism, 
although to a lesser extent than in the undescend-
ed testicle.9,11,13 We could not assess the risk of 
cancer in the contralateral testis, nor could we as-
sess the effect of age at unilateral orchiopexy on 
the risk of cancer in the contralateral testis, be-
cause information on laterality is not available in 
the registries used in our study.
Despite unambiguous recommendations for 
early treatment,4,6 a proportion of boys with crypt-
orchidism are still left untreated until much later 
in life.21,22 Sweden has a well-developed nation-
wide system to screen for cryptorchidism at sev-
eral points in life, starting with neonatal care and 
continuing at child health care centers and at 
school. Since all checkups are free, attendance at 
these clinics should have been high. Yet in our 
cohort, approximately 5% of the orchiopexies in 
the late 1980s were performed at the age of 13 to 
19 years. This proportion seems to have remained 
unchanged ever since. According to 2005 data 
from the Swedish National Board of Health and 
Welfare, about 6% of the orchiopexies in Sweden 
were performed at the age of 13 years or older. 
In the United Kingdom and the Netherlands, in 
the late 1990s, about 10 to 20% of the orchiopex-
ies were performed at the age of 13 years or old-
er.21,22 According to the Swedish Cancer Registry, 
the cumulative incidence of testicular cancer until 
the age of 54 years in Sweden in 2004 was ap-
proximately 0.5%. Given the relative risks in our 
study, we calculated that 69 boys would need to be 
treated before 13 years of age (instead of at or after 
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that age) to avoid one case of testicular cancer in 
Sweden before the age of 55 years.
In summary, our results indicate that age at 
orchiopexy has an effect on the risk of testicular 
cancer in boys with an undescended testicle; the 
risk among those treated at 13 years of age or 
older was twice the risk among those who were 
treated at younger ages.
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